An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.
Inclusion Criteria:
Exclusion Criteria:
Garden Grove, Arizona, United States
Tuscon, Arizona, United States
Jackson, Florida, United States
Saint Doral, Florida, United States
West Palm, Florida, United States
Calamazoo, Michigan, United States
Sugarland, Texas, United States